Akari Therapeutics Plc (AKTX) financial statements (2020 and earlier)

Company profile

Business Address 24 WEST 40TH STREET
NEW YORK, NY 10018
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 696
Cash and cash equivalents 696
Restricted cash and investments  0
Receivables 0 
Other undisclosed current assets 10
Total current assets: 706
Noncurrent Assets
Property, plant and equipment 00
Intangible assets, net (including goodwill) 0 
Intangible assets, net (excluding goodwill) 0 
Restricted cash and investments 0 
Total noncurrent assets: 00
TOTAL ASSETS: 706
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 52
Accounts payable 41
Accrued liabilities 00
Employee-related liabilities  0
Due to related parties  0
Other undisclosed current liabilities 16(0)
Total current liabilities: 211
Noncurrent Liabilities
Liabilities, other than long-term debt  0
Other liabilities  0
Other undisclosed noncurrent liabilities 00
Total noncurrent liabilities: 00
Total liabilities: 212
Stockholders' equity
Stockholders' equity attributable to parent 495
Common stock 181
Additional paid in capital 8734
Accumulated other comprehensive income 0 
Accumulated deficit (57)(30)
Total stockholders' equity: 495
TOTAL LIABILITIES AND EQUITY: 706

Income statement (P&L) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
Revenues
(Financial Services Revenue)
  1
Cost of revenue
(Financial Services Costs)
 (23) 
Gross profit: (23)1
Operating expenses (31)(10)
Other undisclosed operating income (loss) 23(1)
Operating loss: (31)(10)
Nonoperating income (expense) (15)1
Other nonoperating income  1
Interest and debt expense (3) 
Loss from continuing operations before equity method investments, income taxes: (48)(10)
Other undisclosed income from continuing operations before income taxes 3 
Net loss available to common stockholders, diluted: (45)(10)

Comprehensive Income ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
Net loss: (45)(10)
Comprehensive loss: (45)(10)
Other undisclosed comprehensive income, net of tax, attributable to parent 0 
Comprehensive loss, net of tax, attributable to parent: (45)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: